Ill. Jury Finds For AbbVie In AndroGel Bellwether Trial

Law360 (May 16, 2018, 7:50 PM EDT) -- An Illinois federal jury on Tuesday sided with AbbVie Inc. in the fifth bellwether trial in multidistrict litigation over its testosterone replacement therapy drug AndroGel, finding that the drug didn't cause an Arizona man to develop blood clots in his lungs.

After a trial that began on May 7, the jury found in favor of AbbVie on Arthur Myers and his wife Heathers’ claims that taking AndroGel caused him to suffer pulmonary emboli in February 2008. Like others in the MDL, the Myerses had claimed that AbbVie misleadingly marketed the drug as a safe and effective treatment for age-related lower testosterone....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS